Angiotech Pharmaceuticals Inc. (ANPI, ANP.TO) said that its corporate partner, Boston Scientific (BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention using the Taxus Express Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft surgery.
The overall results demonstrated no statistically significant difference between PCI and CABG in the composite safety endpoint.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.